Sofie de Fine Licht

Sofie de Fine Licht

Auto-generated profile, based on publicly available information

Sofie de Fine Licht

AstraZeneca Nordic, Södertälje, Sweden

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2015 in Acta Oncologica
Verified
Journal Article
Closed access
JWJeanette F. Winther
Jeanette F. Winther
LKLine Kenborg
Line Kenborg
JBJulianne Byrne
Julianne Byrne
LHLars Hjorth
Lars Hjorth
PKPeter Kaatsch
Peter Kaatsch
MHMike M. Hawkins
Mike M. Hawkins
With the advent of multimodality therapy, the overall five-year survival rate from childhood cancer has improved considerably now exceeding 80% in developed European countries. This growing cohort of survivors, with many years of life ahead of them, has raised the necessity for knowledge concerning the risks of adverse long-term sequelae of the life-saving treatments in order to provide optimal screening and care and to identify and provide adequate interventions. Childhood cancer survivor cohorts in Europe. Considerable advantages exist to study late effects in individuals treated for childhood cancer in a European context, including the complementary advantages of large population-based cancer registries and the unrivalled opportunities to study lifetime risks, together with rich and detailed hospital-based cohorts which fill many of the gaps left by the large-scale population-based studies, such as sparse treatment information. Several large national cohorts have been established within Europe to study late effects in individuals treated for childhood cancer including the Nordic Adult Life after Childhood Cancer in Scandinavia study (ALiCCS), the British Childhood Cancer Survivor Study (BCCSS), the Dutch Childhood Oncology Group (DCOG) LATER study, and the Swiss Childhood Cancer Survivor Study (SCCSS). Furthermore, there are other large cohorts, which may eventually become national in scope including the French Childhood Cancer Survivor Study (FCCSS), the French Childhood Cancer Survivor Study for Leukaemia (LEA), and the Italian Study on off-therapy Childhood Cancer Survivors (OTR). In recent years significant steps have been taken to extend these national studies into a larger pan-European context through the establishment of two large consortia - PanCareSurFup and PanCareLIFE. The purpose of this paper is to present an overview of the current large, national and pan-European studies of late effects after childhood cancer. This overview will highlight the strong cooperation across Europe, in particular the EU-funded collaborative research projects PanCareSurFup and PanCareLIFE. Overall goal. The overall goal of these large cohort studies is to provide every European childhood cancer survivor with better care and better long-term health so that they reach their full potential, and to the degree possible, enjoy the same quality of life and opportunities as their peers.

1 June 2014 in The Lancet
Verified
Journal Article
Closed access
SLSofie de Fine Licht
Sofie de Fine Licht
JWJeanette Falck Winther
Jeanette Falck Winther
TGThorgerdur Gudmundsdottir
Thorgerdur Gudmundsdottir
AHAnna Sällfors Holmqvist
Anna Sällfors Holmqvist
TBTrine Gade Bonnesen
Trine Gade Bonnesen
JOJørgen Helge Olsen
Jørgen Helge Olsen

9 May 2017 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
SLSofie de Fine Licht
Sofie de Fine Licht
KRKathrine Rugbjerg
Kathrine Rugbjerg
TGThorgerdur Gudmundsdottir
Thorgerdur Gudmundsdottir
TBTrine G. Bonnesen
Trine G. Bonnesen
PAPeter Haubjerg Asdahl
Peter Haubjerg Asdahl
OGon behalf of the ALiCCS study group
on behalf of the ALiCCS study group
Survivors of childhood cancer are at increased risk for a wide range of late effects. However, no large population-based studies have included the whole range of somatic diagnoses including subgroup diagnoses and all main types of childhood cancers. Therefore, we aimed to provide the most detailed overview of the long-term risk of hospitalisation in survivors of childhood cancer. From the national cancer registers of Denmark, Finland, Iceland, and Sweden, we identified 21,297 5-year survivors of childhood cancer diagnosed with cancer before the age of 20 years in the periods 1943–2008 in Denmark, 1971–2008 in Finland, 1955–2008 in Iceland, and 1958–2008 in Sweden. We randomly selected 152,231 population comparison individuals matched by age, sex, year, and country (or municipality in Sweden) from the national population registers. Using a cohort design, study participants were followed in the national hospital registers in Denmark, 1977–2010; Finland, 1975–2012; Iceland, 1999–2008; and Sweden, 1968–2009. Disease-specific hospitalisation rates in survivors and comparison individuals were used to calculate survivors’ standardised hospitalisation rate ratios (RRs), absolute excess risks (AERs), and standardised bed day ratios (SBDRs) based on length of stay in hospital. We adjusted for sex, age, and year by indirect standardisation. During 336,554 person-years of follow-up (mean: 16 years; range: 0–42 years), childhood cancer survivors experienced 21,325 first hospitalisations for diseases in one or more of 120 disease categories (cancer recurrence not included), when 10,999 were expected, yielding an overall RR of 1.94 (95% confidence interval [95% CI] 1.91–1.97). The AER was 3,068 (2,980–3,156) per 100,000 person-years, meaning that for each additional year of follow-up, an average of 3 of 100 survivors were hospitalised for a new excess disease beyond the background rates. Approximately 50% of the excess hospitalisations were for diseases of the nervous system (19.1% of all excess hospitalisations), endocrine system (11.1%), digestive organs (10.5%), and respiratory system (10.0%). Survivors of all types of childhood cancer were at increased, persistent risk for subsequent hospitalisation, the highest risks being those of survivors of neuroblastoma (RR: 2.6 [2.4–2.8]; n = 876), hepatic tumours (RR: 2.5 [2.0–3.1]; n = 92), central nervous system tumours (RR: 2.4 [2.3–2.5]; n = 6,175), and Hodgkin lymphoma (RR: 2.4 [2.3–2.5]; n = 2,027). Survivors spent on average five times as many days in hospital as comparison individuals (SBDR: 4.96 [4.94–4.98]; n = 422,218). The analyses of bed days in hospital included new primary cancers and recurrences. Of the total 422,218 days survivors spent in hospital, 47% (197,596 bed days) were for new primary cancers and recurrences. Our study is likely to underestimate the absolute overall disease burden experienced by survivors, as less severe late effects are missed if they are treated sufficiently in the outpatient setting or in the primary health care system. Childhood cancer survivors were at increased long-term risk for diseases requiring inpatient treatment even decades after their initial cancer. Health care providers who do not work in the area of late effects, especially those in primary health care, should be aware of this highly challenged group of patients in order to avoid or postpone hospitalisations by prevention, early detection, and appropriate treatments.

3 February 2015 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
TGThorgerdur Gudmundsdottir
Thorgerdur Gudmundsdottir
JWJeanette F. Winther
Jeanette F. Winther
SLSofie de Fine Licht
Sofie de Fine Licht
TBTrine G. Bonnesen
Trine G. Bonnesen
PAPeter H. Asdahl
Peter H. Asdahl
OGon behalf of the ALiCCS study group
on behalf of the ALiCCS study group
The lifetime risk for cardiovascular disease in a large cohort of childhood cancer survivors has not been fully assessed. In a retrospective population‐based cohort study predicated on comprehensive national health registers, we identified a cohort of 32,308 one‐year survivors of cancer diagnosed before the age of 20 in the five Nordic countries between the start of cancer registration in the 1940s and 1950s to 2008; 211,489 population comparison subjects were selected from national population registers. Study subjects were linked to national hospital registers, and the observed numbers of first hospital admission for cardiovascular disease among survivors were compared with the expected numbers derived from the population comparison cohort. Cardiovascular disease was diagnosed in 2,632 childhood cancer survivors (8.1%), yielding a standardized hospitalization rate ratio (RR) of 2.1 (95% CI 2.0–2.2) and an overall absolute excess risk (AER) of 324 per 100,000 person‐years. At the end of follow‐up 12% of the survivors were ≥ 50 years of age and 4.5% ≥ 60 years of age. Risk estimates were significantly increased throughout life, with an AER of ∼500–600 per 100,000 person‐years at age ≥ 40. The highest relative risks were seen for heart failure (RR, 5.2; 95% CI 4.5–5.9), valvular dysfunction (4.6; 3.8–5.5) and cerebrovascular diseases (3.7; 3.4–4.1). Survivors of hepatic tumor, Hodgkin lymphoma and leukemia had the highest overall risks for cardiovascular disease, although each main type of childhood cancer had increased risk with different risk profiles. Nordic childhood cancer survivors are at markedly increased risk for cardiovascular disorders throughout life. These findings indicate the need for preventive interventions and continuous follow‐up for this rapidly growing population.

1 April 2014 in European Journal of Cancer
Verified
Journal Article
Closed access
AHAnna Sällfors Holmqvist
Anna Sällfors Holmqvist
JOJørgen H. Olsen
Jørgen H. Olsen
KAKlaus Kaae Andersen
Klaus Kaae Andersen
SLSofie de Fine Licht
Sofie de Fine Licht
LHLars Hjorth
Lars Hjorth
JWJeanette Falck Winther
Jeanette Falck Winther

20 July 2015 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
PAPeter H. Asdahl
Peter H. Asdahl
JWJeanette F. Winther
Jeanette F. Winther
TBTrine G. Bonnesen
Trine G. Bonnesen
SLSofie De Fine Licht
Sofie De Fine Licht
TGThorgerdur Gudmundsdottir
Thorgerdur Gudmundsdottir
OGon behalf of the ALiCCS Study Group
on behalf of the ALiCCS Study Group